Selection of Gastrectomy Type for Gastric Cancer
For clinically node-positive (cN+) or T2-T4a gastric tumors, choose distal (subtotal) gastrectomy when adequate proximal resection margins can be achieved; otherwise, perform total gastrectomy. 1
Decision Algorithm Based on Tumor Stage and Location
For Advanced Disease (cN+ or T2-T4a tumors):
The choice between total and distal gastrectomy hinges on achieving adequate proximal resection margins 1:
Required Proximal Margins:
- T2 or deeper tumors with expansive growth (Types 1 and 2): minimum 3 cm
- Infiltrative growth pattern (Types 3 and 4): minimum 5 cm
- T1 tumors: 2 cm gross margin 1
When frozen section examination is advisable:
- When the above margin rules cannot be observed
- For tumors invading the esophagus (5-cm margin not mandatory, but R0 resection must be confirmed) 1
Mandatory Total Gastrectomy Situations:
- Pancreatic invasion requiring pancreatectomy (regardless of tumor location) 1
- Greater curvature tumors with metastasis to No. 4sb lymph nodes (even if primary tumor could be removed by distal gastrectomy, total gastrectomy with splenectomy should be considered) 1, 2
- Proximal tumors where adequate proximal margin cannot be achieved with subtotal resection 3, 4
For Early Disease (cT1cN0 tumors):
Multiple gastric resection options exist based on tumor location 1:
- Distal gastrectomy: For distal tumors (standard removes two-thirds of stomach, preserves cardia)
- Pylorus-preserving gastrectomy: For middle-third tumors with distal border ≥4 cm from pylorus
- Proximal gastrectomy: For proximal tumors where >50% of distal stomach can be preserved
- Total gastrectomy: When location or extent precludes organ-preserving approaches
Quality of Life Considerations
Subtotal gastrectomy provides superior quality of life outcomes when oncologically appropriate 5:
- Significantly less postoperative weight loss (p<0.02)
- Fewer daily meals required (p<0.001)
- Lower frequency of bowel movements (p=0.031)
- Better scores for disease/therapy-related symptoms and physical function (p<0.02)
Critical caveat: Preservation of the gastric remnant must never compromise oncological radicality 5. The improved quality of life is meaningless if inadequate margins lead to local recurrence.
Evidence Regarding Survival Outcomes
The evidence shows no survival advantage for routine total gastrectomy when adequate margins can be achieved with subtotal resection:
- For distal and middle-third tumors, subtotal gastrectomy achieves equivalent or superior 5-year survival compared to total gastrectomy 6, 7
- A recent U.S. study found subtotal gastrectomy may have a survival benefit for stage III gastric cancers (adjusted HR 2.7 for total vs subtotal, p<0.05) 8
- Multicentric tumors are rare, and recurrences confined to the gastric stump after subtotal gastrectomy are extremely uncommon 6
Special Considerations for Poorly Cohesive Carcinoma
Despite concerns about submucosal spread patterns in poorly cohesive carcinoma (PCC), recent evidence supports subtotal gastrectomy for mid- and distal PCC when adequate margins are achieved. A 2025 study found pathological stage—not type of surgery—was the only independent factor affecting overall survival 9. However, ensure meticulous attention to achieving the 5-cm margin recommended for infiltrative growth patterns.
Lymphadenectomy Requirements
The extent of lymph node dissection is independent of whether total or subtotal gastrectomy is performed 6:
- D2 lymphadenectomy is indicated for cN+ or cT2-T4 tumors 1, 10
- D1+ lymphadenectomy for cT1N0 tumors (except very select early cases) 1
- Minimum 15 lymph nodes should be examined for reliable staging 10
Common Pitfalls to Avoid
- Never perform total gastrectomy "en principe" for all gastric cancers—this increases morbidity without oncological benefit when adequate margins can be achieved with subtotal resection 6
- Do not rely solely on preoperative assessment of margins—use intraoperative frozen section when margin adequacy is uncertain 1
- Avoid routine distal pancreatectomy with total gastrectomy for distal two-thirds tumors (adverse effects documented in randomized trials) 3, 4, 11